IMPDH1: Inosine-5'-monophosphate dehydrogenase 1
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on IMPDH1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| RibavirinBoxed warning | Approved | Bausch Health | Small molecule | InhibitorInosine-5'-monophosphate dehydrogenase 1 inhibitor | 7 |
| Merimepodib | Phase 2 | ViralClear Pharmaceuticals, Inc. | Small molecule | InhibitorInosine-5'-monophosphate dehydrogenase 1 inhibitor | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 7 in all, from ClinicalTrials.gov.| Treatment of CKD Patients With HCV | Ribavirin | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | Aug 18, 2026 |
| UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF | Ribavirin | Phase 2 | Recruiting | Liverpool School of Tropical Medicine | Mar 6, 2025 |
| Assessing Antiviral Treatments in Early Symptomatic RSV | Ribavirin | Phase 2 | Recruiting | University of Oxford | Jul 5, 2024 |
| LAssa Fever Adjunct Treatment With DEXamethasone | Ribavirin | Phase 2 | Recruiting | Bernhard Nocht Institute for Tropical Medicine | Jan 25, 2024 |
| ISTH/ANRS 0409s INTEGRATE Lassa Fever Study | Ribavirin | Phase 2 / Phase 3 | Recruiting | Irrua Specialist Teaching Hospital | Jan 18, 2024 |
| The Efficacy of Vosevi in Treating DAA-experienced Patients | Ribavirin | — | Recruiting | The Third Affiliated Hospital of Guangzhou Medical University | Dec 22, 2023 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | Ribavirin | — | Recruiting | Duke University | Feb 20, 2020 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Retinitis pigmentosa 10
- 0.68
- Leber congenital amaurosis
- 0.63
- Chronic hepatitis C virus infection
- 0.60
- Hepatitis C virus infection
- 0.60
- Leber congenital amaurosis 11
- 0.60
- Cirrhosis of liver
- 0.60
- Viral infectious disease
- 0.46
- Crohn disease
- 0.45
- Inherited retinal dystrophy
- 0.42
Genes and related targets
Complexes and families that share a gene with this target- Genes
- IMPDH1
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1822, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P20839, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets